• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training

Cystic Fibrosis Pipeline Dashboard, H1 2018

Scope of report

  • The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis.
  • The report assesses Cystic Fibrosis pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • The report reviews Cystic Fibrosis pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report covers pipeline products based on various stages of development for Cystic Fibrosis ranging from discovery to pre-registration and undisclosed stages.

Companies Covered:

AstraZeneca, Genentech, Genzyme Corporation, Protease Sciences, Merck & Co, Milkhaus Laboratory, PPL Therapeutics PLC, Lantibio, Inex Pharmaceuticals Corporation, Valentis, Ixion Biotechnology, Vyrex Corporation, GlaxoSmithKline, Cyclacel Pharmaceuticals, Targeted Genetics Corporation, Copernicus Therapeutics, CBR Laboratories, Bayer, Inspire Pharmaceuticals, Genta, Polydex Pharmaceuticals, Boehringer Ingelheim, Chiesi Farmaceutici, Vertex Pharmaceuticals

Key Drugs:

ICI 200880, Midesteine, CE 1037, TLC C 53, Dornase alfa, ALP 242, DF 1283, AL 721, Ajulemic acid, Cystic fibrosis gene therapy – CFTR-cationic lipid complex, Alpha-1 antitrypsin gene therapy, Uridine triphosphate, L 694458, ML 03, Lancovutide, Tyloxapol, IxC 162, Vantox, Elubrixin, Acetylcysteine lysinate, Depelestat, Seliciclib, DAX

Publisher: Pharmintel

Format: Microsoft Excel
Sheets: 8

  • Single Use:  $300
  • Site License: $500
  • Global License: $800

Report Inquiry

Leave a Reply

Your email address will not be published. Required fields are marked *

+91 9643310025, 9643312749
© 2024 Pharmintel